Back to Search
Start Over
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
- Source :
- Clinical Lung Cancer; Jan2017, Vol. 18 Issue 1, p68-68, 1p, 3 Charts
- Publication Year :
- 2017
Details
- Language :
- English
- ISSN :
- 15257304
- Volume :
- 18
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Clinical Lung Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 121291463
- Full Text :
- https://doi.org/10.1016/j.cllc.2016.09.002